Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Liabilities and Shareholders Equity (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $949.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 21.0% year-over-year to $949.9 million, compared with a TTM value of $3.4 billion through Dec 2025, up 12.52%, and an annual FY2025 reading of $949.9 million, up 21.0% over the prior year.
  • Liabilities and Shareholders Equity was $949.9 million for Q4 2025 at Amicus Therapeutics, up from $868.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $956.7 million in Q3 2021 and bottomed at $700.5 million in Q1 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $800.5 million, with a median of $786.7 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity dropped 20.61% in 2022, then grew 21.0% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $905.1 million in 2021, then fell by 19.99% to $724.2 million in 2022, then grew by 7.42% to $777.9 million in 2023, then increased by 0.92% to $785.0 million in 2024, then rose by 21.0% to $949.9 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for FOLD at $949.9 million in Q4 2025, $868.8 million in Q3 2025, and $815.3 million in Q2 2025.